{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:02Z","timestamp":1787016902358,"version":"build-2736575974"},"reference-count":13,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,5,20]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Trastuzumab is a humanised, monoclonal antibody that interferes with the human epidermal growth factor receptor 2 (HER2)\/neu receptor and binds selectively to the HERB2 protein. It has been shown to prolong survival of patients with HER2-positive advanced uterine serous carcinoma.<\/jats:p>\n                  <jats:p>\n                    We report the case of a woman in her 70s with HER2-positive metastatic papillary serous endometrial adenocarcinoma, who experienced severe thrombocytopenia related to trastuzumab administration. One week after the first dose of carboplatin\/paclitaxel\/trastuzumab combination chemotherapy, the patient was admitted to the hospital with vaginal bleeding, melena, petechiae and platelet counts of 0\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L. The patient was suspected to have a severe trastuzumab-induced thrombocytopenia. A rapid and complete recovery was observed after multiple platelet transfusions, high-dose IV corticosteroids and immunoglobulin.\n                  <\/jats:p>\n                  <jats:p>Among the 13 reported cases of trastuzumab-induced thrombocytopenia, this is the first case reported in the literature occurring in a patient with a gynecologic malignancy.<\/jats:p>","DOI":"10.1136\/bcr-2023-255181","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:35:29Z","timestamp":1685615729000},"page":"e255181","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Severe thrombocytopenia after trastuzumab in a patient with HER2-positive serous endometrial cancer"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-1376","authenticated-orcid":false,"given":"Celia","family":"Kucera","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chappell","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2025082711091594000_16.6.e255181.1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ygyno.2021.07.033","article-title":"Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine Serous Carcinomas that Overexpress Her2\/Neu","volume":"163","author":"Tymon-Rosario","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025082711091594000_16.6.e255181.2","first-page":"S105","article-title":"Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95 Suppl 1","author":"Creasman","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"2025082711091594000_16.6.e255181.3","unstructured":"NCCN Clinical Practice Guidelines in Oncology . NCCN guidelines\u00ae for endometrial carcinoma V.1.2022. \u00a9 national comprehensive cancer network; 2022."},{"key":"2025082711091594000_16.6.e255181.4","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2001.19.20.4048","article-title":"Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study","volume":"19","author":"Hoskins","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025082711091594000_16.6.e255181.5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.5966"},{"key":"2025082711091594000_16.6.e255181.6","doi-asserted-by":"crossref","DOI":"10.3390\/biom13030499","article-title":"Novel insights into molecular mechanisms of endometrial diseases","volume":"13","author":"Golia D\u2019Aug\u00e8","year":"2023","journal-title":"Biomolecules"},{"key":"2025082711091594000_16.6.e255181.7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062241","article-title":"Recent advances in endometrial cancer management","volume":"12","author":"Di Donato","year":"2023","journal-title":"J Clin Med"},{"key":"2025082711091594000_16.6.e255181.8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2021.04.029","article-title":"Uterine Serous carcinoma","volume":"162","author":"Bogani","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025082711091594000_16.6.e255181.9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/his.14381","article-title":"Performance of a Her2 testing algorithm specific for P53-abnormal endometrial cancer","volume":"79","author":"Vermij","year":"2021","journal-title":"Histopathology"},{"key":"2025082711091594000_16.6.e255181.10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PAS.0000000000002030","article-title":"Her2 IHC expression and Gene amplification in P53-aberrant high-grade endometrial Endometrioid carcinoma suggests that this population may benefit from Her2 testing and targeted therapy","volume":"47","author":"Joehlin-Price","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"2025082711091594000_16.6.e255181.11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13691-021-00520-z","article-title":"Drug-induced thrombocytopenia associated with Trastuzumab in a patient with Her2-positive recurrent gastric cancer","volume":"11","author":"Takano","year":"2022","journal-title":"Int Cancer Conf J"},{"key":"2025082711091594000_16.6.e255181.12","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-6-400","article-title":"Severe thrombocytopenia after Trastuzumab Retreatment: a case report","volume":"6","author":"Pino","year":"2013","journal-title":"BMC Res Notes"},{"key":"2025082711091594000_16.6.e255181.13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.36129\/jog.2022.34","article-title":"The role of preoperative Frailty assessment in patients affected by gynecological cancer: a narrative review","volume":"34","author":"D\u2019Oria","year":"2022","journal-title":"Ital J Gynaecol Obstet"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:09:26Z","timestamp":1756318166000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bcr-2023-255181"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255181","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}